Aktiesnakken — Juli 2010
-
flere reduktioner i Us og EU og op i emerging market + japan
-
de skal have 8% - 14% på deres investerede kapital
-
det omregner I lige drenge med deres investering i Genmab/arzerra
-
det var p.a
-
5-fold increase in Biopharm spend since 2006
-
det er os !
-
vildt deres patent udløb har kostet den 3,4 milliarder pund på 3 år
-
bare i US!
-
langsommere uptake i US
-
mon ikke det giver lidt incentiv til at booste RA forsøgene...
-
kurven bliver suppressed yoy
-
vilde vilde tal han kommer her
-
mistet omsætning 4,2 bn pund med 85% margin i us
-
og alligevel har de fortsat stigende omsætning, indtjening og dividende
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind